Tumor Biology

, Volume 35, Issue 12, pp 12459–12465 | Cite as

Downregulation of CPE regulates cell proliferation and chemosensitivity in pancreatic cancer

  • Anan Liu
  • Chenghao Shao
  • Gang Jin
  • Rui Liu
  • Jun Hao
  • Zhuo Shao
  • Quyang Liu
  • Xiangui Hu
Research Article

Abstract

Pancreatic cancer (PC) is one of the most common cancers worldwide and a leading cause of cancer-related death. Discovering novel targets is a key for its therapy. Carboxypeptidase E (CPE), a subtype of the pro-protein convertases, has been shown to be upregulated in many types of cancer, yet its function in PC remains elusive. The expressions of CPE in PC cell lines and cancer patients were investigated by Western blot and qRT-PCR. In PC cell line BX-pc-3, CPE was downregulated and its effect on cancer cell proliferation, migration, cisplatin chemosensitivity, and in vivo tumor growth was analyzed by Western blot, proliferation assay, invasion assay, and in vivo transplantation, respectively. The expression of nuclear factor-kappaB (NF-κB), a possible downstream target of CPE was examined by Western blot upon CPE regulation in PC cells, and the effects of inhibiting NF-κB on PC cell invasion and proliferation were examined. CPE was significantly upregulated in PC cell lines and tumor tissues. Proliferation and invasion assays indicated that downregulation of CPE inhibited cancer cell growth and migration and increased chemosensitivity to cisplatin. Inoculation of small interfering RNA (siRNA) transfected BX-pc-3 cells into null mice demonstrated that downregulation of CPE prevented tumor growth in vivo. NF-κB was directly regulated by CPE in pancreatic cancer, and siRNA-mediated inhibition of NF-κB exerted similar anti-tumor effect as downregulating CPE. Taken together, our results demonstrate that CPE plays an important role in pancreatic cancer. Inhibition of CPE may serve as a potential target for PC therapeutics.

Keywords

Pancreatic cancer CPE NF-κB 

References

  1. 1.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRefGoogle Scholar
  2. 2.
    Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in china cancer registries, 2009. Chin J Cancer Res. 2013;25:10–21.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Hirata K, Egawa S, Kimura Y, Nobuoka T, Oshima H, Katsuramaki T, et al. Current status of surgery for pancreatic cancer. Dig Surg. 2007;24:137–47.PubMedCrossRefGoogle Scholar
  4. 4.
    Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Reznik R, Hendifar AE, Tuli R. Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma. Front Physiol. 2014;5:87.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Satoh K. The molecular mechanism in tumorigenesis and development of pancreatic cancer. Nihon Shokakibyo Gakkai zasshi Jpn J Gastroenterol. 2013;110:2042–50.Google Scholar
  7. 7.
    Fricker LD. Carboxypeptidase E. Annu Rev Physiol. 1988;50:309–21.PubMedCrossRefGoogle Scholar
  8. 8.
    Pla V, Paco S, Ghezali G, Ciria V, Pozas E, Ferrer I, et al. Secretory sorting receptors carboxypeptidase e and secretogranin III in amyloid beta-associated neural degeneration in Alzheimer's disease. Brain Pathol. 2013;23:274–84.PubMedCrossRefGoogle Scholar
  9. 9.
    McGirr R, Guizzetti L, Dhanvantari S. The sorting of proglucagon to secretory granules is mediated by carboxypeptidase E and intrinsic sorting signals. J Endocrinol. 2013;217:229–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Steiner DF. The proprotein convertases. Curr Opin Chem Biol. 1998;2:31–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Naggert JK, Fricker LD, Varlamov O, Nishina PM, Rouille Y, Steiner DF, et al. Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase e mutation which reduces enzyme activity. Nat Genet. 1995;10:135–42.PubMedCrossRefGoogle Scholar
  12. 12.
    Cawley NX, Yanik T, Woronowicz A, Chang W, Marini JC, Loh YP. Obese carboxypeptidase E knockout mice exhibit multiple defects in peptide hormone processing contributing to low bone mineral density. Am J Physiol Endocrinol Metab. 2010;299:E189–97.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Yang L, Zhou Z, Du T, Tan S, Zhnag Y, Jin P. Detection of carboxypeptidase h specific t cells in peripheral blood of latent autoimmune diabetic patients with carboxypeptidase antibody positivity by ELISPOT assay. Zhong nan da xue xue bao Yi xue ban J Cent South Univ Med Sci. 2009;34:1011–6.Google Scholar
  14. 14.
    Murthy SR, Dupart E, Al-Sweel N, Chen A, Cawley NX, Loh YP. Carboxypeptidase e promotes cancer cell survival, but inhibits migration and invasion. Cancer Lett. 2013;341:204–13.PubMedCrossRefGoogle Scholar
  15. 15.
    Cawley NX, Wetsel WC, Murthy SR, Park JJ, Pacak K, Loh YP. New roles of carboxypeptidase E in endocrine and neural function and cancer. Endocr Rev. 2012;33:216–53.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Skalka N, Caspi M, Caspi E, Loh YP, Rosin-Arbesfeld R. Carboxypeptidase E: a negative regulator of the canonical Wnt signaling pathway. Oncogene. 2013;32:2836–47.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Zhou K, Liang H, Liu Y, Yang C, Liu P, Jiang X. Overexpression of CPE-∆N predicts poor prognosis in colorectal cancer patients. Tumour Biol. 2013;34:3691–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Lee TK, Murthy SR, Cawley NX, Dhanvantari S, Hewitt SM, Lou H, et al. An N-terminal truncated carboxypeptidase e splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. J Clin Invest. 2011;121:880–92.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Murthy SR, Pacak K, Loh YP. Carboxypeptidase E: elevated expression correlated with tumor growth and metastasis in pheochromocytomas and other cancers. Cell Mol Neurobiol. 2010;30:1377–81.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Wang CY, Mayo MW, Baldwin Jr AS. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB. Science. 1996;274:784–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-κB in development and progression of human cancer. Virchows Archiv Int J Pathol. 2005;446:475–82.CrossRefGoogle Scholar
  22. 22.
    Lee CH, Jeon YT, Kim SH, Song YS. NF-kappaB as a potential molecular target for cancer therapy. BioFactors. 2007;29:19–35.PubMedCrossRefGoogle Scholar
  23. 23.
    Thomas RP, Farrow BJ, Kim S, May MJ, Hellmich MR, Evers BM. Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery. 2002;132:127–34.PubMedCrossRefGoogle Scholar
  24. 24.
    Xiong HQ, Abbruzzese JL, Lin E, Wang L, Zheng L, Xie K. NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer. 2004;108:181–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Biliran Jr H, Wang Y, Banerjee S, Xu H, Heng H, Thakur A, et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:6075–86.CrossRefGoogle Scholar
  26. 26.
    Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA, Tsao MS. Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol. 1996;148:1763–70.PubMedCentralPubMedGoogle Scholar
  27. 27.
    Zhang L, Mizumoto K, Sato N, Ogawa T, Kusumoto M, Niiyama H, et al. Quantitative determination of apoptotic death in cultured human pancreatic cancer cells by propidium iodide and digitonin. Cancer Lett. 1999;142:129–37.PubMedCrossRefGoogle Scholar
  28. 28.
    Krajnik M, Schafer M, Sobanski P, Kowalewski J, Bloch-Boguslawska E, Zylicz Z, et al. Enkephalin, its precursor, processing enzymes, and receptor as part of a local opioid network throughout the respiratory system of lung cancer patients. Hum Pathol. 2010;41:632–42.PubMedCrossRefGoogle Scholar
  29. 29.
    Chandler NM, Canete JJ, Callery MP. Increased expression of NF-kappa B subunits in human pancreatic cancer cells. J Surg Res. 2004;118:9–14.PubMedCrossRefGoogle Scholar
  30. 30.
    Li Y, Ellis KL, Ali S, El-Rayes BF, Nedeljkovic-Kurepa A, Kucuk O, et al. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas. 2004;28:e90–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003;22:3243–51.PubMedCrossRefGoogle Scholar
  32. 32.
    Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther. 2006;5:483–93.PubMedCrossRefGoogle Scholar
  33. 33.
    Shah SA, Potter MW, Hedeshian MH, Kim RD, Chari RS, Callery MP. Pi-3' kinase and NF-kappaB cross-signaling in human pancreatic cancer cells. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2001;5:603–12. discussion 612–603.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Anan Liu
    • 1
  • Chenghao Shao
    • 1
  • Gang Jin
    • 1
  • Rui Liu
    • 1
  • Jun Hao
    • 1
  • Zhuo Shao
    • 1
  • Quyang Liu
    • 1
  • Xiangui Hu
    • 1
  1. 1.Department of Pancreatic SurgeryChanghai Hospital of Second Military Medical UniversityShanghaiChina

Personalised recommendations